Ilsung Is Co., Ltd. Share Price

Equities

A003120

KR7003120003

Pharmaceuticals

End-of-day quote Korea S.E. 23:00:00 28/04/2024 BST 5-day change 1st Jan Change
19,860 KRW +0.40% Intraday chart for Ilsung Is Co., Ltd. +5.58% -16.03%

Financials

Sales 2022 61.25B 44.59M 3.55B Sales 2023 78.05B 56.82M 4.53B Capitalization 165B 120M 9.56B
Net income 2022 105B 76.62M 6.11B Net income 2023 -20.94B -15.25M -1.22B EV / Sales 2022 -2.85 x
Net cash position 2022 300B 218M 17.39B Net cash position 2023 235B 171M 13.65B EV / Sales 2023 -0.9 x
P/E ratio 2022
1.2 x
P/E ratio 2023
-7.9 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 3.99%
More Fundamentals * Assessed data
Dynamic Chart
Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023. CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023. CI
Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback announced on February 13, 2023, has expired with 598,487 shares, representing 29.77% for KRW 14,994.85 million. CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023. CI
Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Ilsung Pharmaceuticals Co., Ltd. announces an Equity Buyback for KRW 15,000 million worth of its shares. CI
Ilsung Pharmaceuticals Co., Ltd. authorizes a Buyback Plan. CI
Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 9, 2022. CI
Ilsung Pharmaceuticals Co. Ltd.’s Equity Buyback announced on February 9, 2022, has expired with 50,935 shares, representing 3.32% for KRW 4,220.26 million. CI
Ilsung Pharmaceuticals Co., Ltd. announces an Equity Buyback for 53,200 shares. CI
Ilsung Pharmaceuticals Co., Ltd. authorizes a Buyback Plan. CI
Cheil Industries Inc. completed the acquisition of Samsung C&T Corporation from a group of shareholders. CI
Ilsung Seeks To Sell Stake In Samsung C&T CI
More news
1 day+0.40%
1 week+5.58%
Current month-6.76%
1 month-6.98%
3 months-6.54%
6 months-0.70%
Current year-16.03%
More quotes
1 week
19 080.00
Extreme 19080
20 000.00
1 month
18 310.00
Extreme 18310
21 750.00
Current year
18 310.00
Extreme 18310
25 650.00
1 year
18 310.00
Extreme 18310
29 000.00
3 years
13 780.00
Extreme 13780
38 000.00
5 years
13 780.00
Extreme 13780
38 000.00
10 years
13 780.00
Extreme 13780
38 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 38 -
Chief Executive Officer 68 -
Director/Board Member 57 -
Members of the board TitleAgeSince
Chief Executive Officer 68 -
Corporate Officer/Principal 64 -
Director/Board Member 41 -
More insiders
Date Price Change Volume
28/04/24 19,860 +0.40% 3 715
26/04/24 19,780 +0.15% 4,580
25/04/24 19,750 +0.25% 9,214
24/04/24 19,700 -0.76% 6,263
23/04/24 19,850 +3.28% 11,132

End-of-day quote Korea S.E., April 28, 2024

More quotes
Ilsung IS Co Ltd, formerly Ilsung Pharmaceutical Co Ltd, is a Korea-based company mainly engaged in the pharmaceuticals manufacture and sale business. The Company’s products consist of penicillin antibiotics, contrast mediums, digestive drugs, cardiovascular agents, antihistamines, anti-diabetics, bone disease drugs, analgesics, muscle relaxants, anesthetics, skin disease drugs, cardiovascular drugs, psychiatry drugs, antivirals, antipyretics and others. The Company distributes its products through wholesalers, hospitals, pharmacies and others. The Company also provides consignment production services.
More about the company
  1. Stock Market
  2. Equities
  3. A003120 Stock